Table 1.
Demographic and clinical characteristics of study population.
| HCM (n = 30) | ATTR (n = 30) | p Value | |
|---|---|---|---|
| Age, years | 58 [54–73] | 69 [62–78] | <0.001 |
| Males | 24 (80%) | 23 (77%) | 0.754 |
| Body surface area, m2.7 | 1.9 [1.7–2.0] | 1.7 [1.6–1.9] | <0.001 |
| Systolic BP, mm Hg | 128.8 ± 11.9 | 128.5 ± 12.7 | 0.925 |
| Diastolic BP, mm Hg | 77.4 ± 12.3 | 80.7 ± 7.9 | 0.226 |
| Mean BP, mm Hg | 94.5 ± 10.3 | 96.6 ± 7.4 | 0.375 |
| Pulse pressure, mm Hg | 51.4 ± 13.5 | 47.9 ±13.5 | 0.311 |
| Heart rate, bpm | 67.2 ± 11.3 | 68.4 ± 11.2 | 0.690 |
| NYHA class I–III | 1.4 ± 0.56 | 1.9 ± 0.46 | <0.001 |
| Dyspnea | 7 (23%) | 23 (77%) | <0.001 |
| Family history of SD | 7 (23%) | 3 (10%) | 0.166 |
| Implantable cardioverter defibrillator | 3 (10%) | 1 (3%) | NA |
| Therapy | |||
| Beta-blockers | 25 (83%) | 10 (33%) | <0.001 |
| Calcium antagonists | 11 (37%) | 5 (17%) | 0.080 |
| ACE-inhibitors | 8 (27%) | 2 (7%) | 0.07 |
| ARB | 1 (3%) | 7 (23%) | 0.023 |
| Statins | 6 (20%) | 15 (50%) | 0.015 |
| Anti-coagulants | 6 (20%) | 6 (20%) | 1.000 |
| Anti-platelet drugs | 5 (17%) | 9 (30%) | 0.222 |
| Diuretics | 4 (13%) | 17 (57%) | <0.001 |
| Tafamidis 65 mg | - | 30 (100%) | NA |
Values are numbers (%), mean ± SD, or median values [IQR], as appropriate. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor antagonists; ATTR, wild-type transthyretin cardiac amyloidosis; BP, blood pressure; HCM, nonobstructive hypertrophic cardiomyopathy; NA, not available/performed; SCD, sudden cardiac death.